Menitrazepam is a cyclohexene-substituted benzodiazepine. It is a muscle relaxant.

Mefeclorazine is a non-steroidal anti-inflammatory drug. It inhibits prostaglandin synthesis.

Axomadol is a centrally active analgesic agent with opioid agonistic properties and with inhibitory effects on the reuptake of the monoamines noradrenaline and, to serotonin [5‐hydroxytrypyamine (5‐HT)]. The drug participated in phase II clinical trials in the treatment of patients with moderate to severe chronic low back pain. As a result, the axomadol didn’t meet predetermined study endpoint, and studies were discontinued.

Alletorphine (R & S 218-M) is a potent analgesic said to have a reduced respiratory depressant action. It was isolated by Bentley and Hardy (1967) while they were examining a series of derivatives of tetrahydrothebaine of which the potent analgesic etorphine (propylorvinolhydrochloride: M99 Reckitt) is a member. R&S 218-M bears the same relationship to etorphine as does nalorphine to morphine. It has been the subject of experiments in animals and human volunteers.

Sulmepride (also known as TER 1546) is a sulfamoylbenzamide derivative patented by Heumann, Ludwig, und Co. G.m.b.H. as neuroleptic. Sulmepride acts as a specific antagonist of dopamine D-2 receptors.

Traboxopine (EGYT-2509) revealed specific dopamine-antagonistic activity with potentially minimal undesirable side effects. EGYT-2509 behaved as a dopamine receptor antagonist in all functional in vitro biochemical-pharmacological tests (striatal adenylate cyclase, striatal dopamine release, prolactin release from pituitary). The drug exhibited a marked preference for adenylate cyclase-coupled (D1) dopamine receptors, followed by the 3H-spiperone displacing potency at striatal receptors. Traboxopine exerts pharmacological and biochemical effects that seem to be partially similar to those of traditional neuroleptics, except for some undesirable side effects (e.g. cataleptogenic, influencing prolactin level). Traboxopine proved to be diversely influential on the dopaminergic components of the integration of sympathetic output and somato-autonomic reflexes. The apomorphine-induced stereotypy was potentiated by lower, and antagonized by higher doses of EGYT-2509. The in vitro potency of EGYT-2509 to block dopamine-mediated inhibition of prolactin release was weaker by three orders of magnitude than that of haloperidol.

Amibegron (SR 58611A or SR 58611) is a highly selective agonist for atypical beta3-adrenoceptors. It stimulates neuronal activity in a specific area of the prefrontal cortex and also inhibits intestinal motility. Amibegron was in phase III trials worldwide for the treatment of depression and generalised anxiety disorder but development of the product was discontinued in 2008. Amibegron has been tested for its potential as a treatment for irritable bowel syndrome.

Etoprindole is an antiinflammatory agent.

Cinfenine is diphenylmethoxyethylamine derivative that acts as antidepressant in some animal models.